Among these, homologues MKT-077 and YM-01 (Figure 5) were considered as candidate in AD treatment for their ability to rapidly and potently reduce Tau levels in vitro and ex vivo, by targeting Hsp70 [104,105]. This evidence concerns the gene MAPT and Alzheimer disease.